[HTML][HTML] The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases
…, M Boussinesq, SJ Brooker, AS Brown… - PLoS neglected …, 2014 - journals.plos.org
The publication of the Global Burden of Disease Study 2010 (GBD 2010) and the accompanying
collection of Lancet articles in December 2012 provided the most comprehensive …
collection of Lancet articles in December 2012 provided the most comprehensive …
[HTML][HTML] Immunogenicity of a DNA vaccine candidate for COVID-19
…, D Li, L Bao, J Liu, W Deng, C Qin, AS Brown… - Nature …, 2020 - nature.com
The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for
the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to …
the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to …
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical …
…, M Giffear, AS Brown, K Marcozzi-Pierce, D Shah… - The Lancet, 2015 - thelancet.com
Background Despite preventive vaccines for oncogenic human papillomaviruses (HPVs),
cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and can …
cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and can …
[HTML][HTML] Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
…, MP Mammen, J Lee, MJ Dallas, AS Brown… - …, 2021 - thelancet.com
Background A vaccine against SARS-CoV-2 is of high urgency. Here the safety and
immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of …
immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of …
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in …
…, R Spitz, RJ Juba, J Lee, M Dallas, AS Brown… - MedRxiv, 2021 - medrxiv.org
Background Vaccines against SARS-CoV-2 are still urgently needed as only 5% of the global
population has been vaccinated. Here we report the safety and immunogenicity of a DNA …
population has been vaccinated. Here we report the safety and immunogenicity of a DNA …
SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial
…, J Lee, M Dallas, A Shah Brown… - The Journal of …, 2022 - academic.oup.com
Background Additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines that are safe and effective as primary vaccines and boosters remain urgently needed …
vaccines that are safe and effective as primary vaccines and boosters remain urgently needed …
Neglected tropical disease vaccines
PJ Hotez, AS Brown - Biologicals, 2009 - Elsevier
The neglected tropical diseases or ‘NTDs’ represent the most common infections of the
world's one billion poorest people. Unlike the better known acute or emerging infections, the …
world's one billion poorest people. Unlike the better known acute or emerging infections, the …
[HTML][HTML] Health education through analogies: preparation of a community for clinical trials of a vaccine against hookworm in an endemic area of Brazil
…, R de Cassia Marques, A Shah Brown… - PLoS neglected …, 2010 - journals.plos.org
Background Obtaining informed consent for clinical trials is especially challenging when
working in rural, resource-limited areas, where there are often high levels of illiteracy and lack …
working in rural, resource-limited areas, where there are often high levels of illiteracy and lack …
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
…, C Sarver, AU Wells, V Strand, EL Matteson, KK Brown… - Thorax, 2014 - thorax.bmj.com
Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack
of consensus on appropriate outcome measures for reliably assessing treatment response. …
of consensus on appropriate outcome measures for reliably assessing treatment response. …
Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm
ME Bottazzi, AS Brown - Expert review of vaccines, 2008 - Taylor & Francis
This article provides an overview of the advances in product development and technology
transfer of the vaccine against human hookworm, with particular emphasis on the lessons …
transfer of the vaccine against human hookworm, with particular emphasis on the lessons …
